- Home
- EVOK vs QLGN Comparison
EVOK vs QLGN Comparison
Compare EVOK & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- QLGN
- Stock Information
- Founded
- EVOK 2007
- QLGN 1996
- Country
- EVOK United States
- QLGN United States
- Employees
- EVOK N/A
- QLGN 4
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- QLGN Health Care
- Exchange
- EVOK Nasdaq
- QLGN Nasdaq
- Market Cap
- EVOK 7.6M
- QLGN 5.8M
- IPO Year
- EVOK 2013
- QLGN N/A
- Fundamental
- Price
- EVOK $5.15
- QLGN $2.85
- Analyst Decision
- EVOK
- QLGN
- Analyst Count
- EVOK 0
- QLGN 0
- Target Price
- EVOK N/A
- QLGN N/A
- AVG Volume (30 Days)
- EVOK 26.0K
- QLGN 3.4M
- Earning Date
- EVOK 11-07-2025
- QLGN 11-14-2025
- Dividend Yield
- EVOK N/A
- QLGN N/A
- EPS Growth
- EVOK N/A
- QLGN N/A
- EPS
- EVOK N/A
- QLGN N/A
- Revenue
- EVOK $12,794,859.00
- QLGN N/A
- Revenue This Year
- EVOK $57.38
- QLGN N/A
- Revenue Next Year
- EVOK $59.57
- QLGN N/A
- P/E Ratio
- EVOK N/A
- QLGN N/A
- Revenue Growth
- EVOK 70.02
- QLGN N/A
- 52 Week Low
- EVOK $1.94
- QLGN $1.61
- 52 Week High
- EVOK $9.88
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- EVOK 57.04
- QLGN 39.72
- Support Level
- EVOK $4.53
- QLGN $2.66
- Resistance Level
- EVOK $5.19
- QLGN $3.36
- Average True Range (ATR)
- EVOK 0.28
- QLGN 0.55
- MACD
- EVOK 0.07
- QLGN -0.17
- Stochastic Oscillator
- EVOK 91.26
- QLGN 5.74
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.